Literature DB >> 20733037

Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.

Sonia Burrel1, Claire Deback, Henri Agut, David Boutolleau.   

Abstract

The molecular mechanisms of herpes simplex virus (HSV) resistance to antiviral drugs interfering with viral DNA synthesis reported so far rely on the presence of mutations within UL23 (thymidine kinase [TK]) and UL30 (DNA polymerase) genes. The interpretation of genotypic antiviral resistance assay results requires the clear distinction between resistance mutations and natural interstrain sequence variations. The objectives of this work were to describe extensively the natural polymorphism of UL23 TK and UL30 DNA polymerase among HSV-1 and HSV-2 strains and the amino acid changes potentially associated with HSV resistance to antivirals. The sequence analysis of the full-length UL23 and UL30 genes was performed. Ninety-four drug-sensitive clinical isolates (43 HSV-1 and 51 HSV-2) and 3 laboratory strains (KOS, gHSV-2, and MS2) were studied for natural polymorphism, and 25 clinical isolates exhibiting phenotypic traits of resistance to antivirals were analyzed for drug resistance mutations. Our results showed that TK and DNA polymerase are highly conserved among HSV strains, with a weaker variability for HSV-2 strains. This study provided a precise map of the natural polymorphism of both viral enzymes among HSV-1 and HSV-2 isolates, with the identification of 15 and 51 polymorphisms never previously described for TK and DNA polymerase, respectively, which will facilitate the interpretation of genotypic antiviral-resistant testing. Moreover, the genotypic characterization of 25 drug-resistant HSV isolates revealed 8 new amino acid changes located in TK and potentially accounting for acyclovir (ACV) resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20733037      PMCID: PMC2976144          DOI: 10.1128/AAC.00669-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  55 in total

1.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir.

Authors:  R T Sarisky; M R Quail; P E Clark; T T Nguyen; W S Halsey; R J Wittrock; J O'Leary Bartus; M M Van Horn; G M Sathe; S Van Horn; M D Kelly; T H Bacon; J J Leary
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2.

Authors:  R T Sarisky; T T Nguyen; K E Duffy; R J Wittrock; J J Leary
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

4.  Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients.

Authors:  F Morfin; G Souillet; K Bilger; T Ooka; M Aymard; D Thouvenot
Journal:  J Infect Dis       Date:  2000-06-19       Impact factor: 5.226

Review 5.  Herpes simplex virus resistance to antiviral drugs.

Authors:  Florence Morfin; Danielle Thouvenot
Journal:  J Clin Virol       Date:  2003-01       Impact factor: 3.168

6.  Herpes simplex virus isolates with reduced adefovir susceptibility selected in vivo by foscarnet therapy.

Authors:  Julie Bestman-Smith; Guy Boivin
Journal:  J Med Virol       Date:  2002-05       Impact factor: 2.327

7.  Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation.

Authors:  M C Dignani; A Mykietiuk; M Michelet; D Intile; L Mammana; P Desmery; G Milone; S Pavlovsky
Journal:  Bone Marrow Transplant       Date:  2002-02       Impact factor: 5.483

Review 8.  Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms.

Authors:  Christian Gilbert; Julie Bestman-Smith; Guy Boivin
Journal:  Drug Resist Updat       Date:  2002-04       Impact factor: 18.500

9.  Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.

Authors:  Doris Chibo; Anne Mijch; Richard Doherty; Christopher Birch
Journal:  J Clin Virol       Date:  2002-08       Impact factor: 3.168

10.  Assessing the contribution of the herpes simplex virus DNA polymerase to spontaneous mutations.

Authors:  Karen E Duffy; Matthew R Quail; Tammy T Nguyen; Robert J Wittrock; Joan O Bartus; Wendy M Halsey; Jeffry J Leary; Teresa H Bacon; Robert T Sarisky
Journal:  BMC Infect Dis       Date:  2002-05-07       Impact factor: 3.090

View more
  27 in total

1.  Quantification and analysis of thymidine kinase expression from acyclovir-resistant G-string insertion and deletion mutants in herpes simplex virus-infected cells.

Authors:  Dongli Pan; Donald M Coen
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Genetic Diversity within Alphaherpesviruses: Characterization of a Novel Variant of Herpes Simplex Virus 2.

Authors:  Sonia Burrel; Nathalie Désiré; Julien Marlet; Laurent Dacheux; Sophie Seang; Eric Caumes; Hervé Bourhy; Henri Agut; David Boutolleau
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

4.  Differences in the Likelihood of Acyclovir Resistance-Associated Mutations in the Thymidine Kinase Genes of Herpes Simplex Virus 1 and Varicella-Zoster Virus.

Authors:  Hikaru Fujii; Shizuko Harada; Tomoki Yoshikawa; Souichi Yamada; Natsumi Omura; Miho Shibamura; Takuya Inagaki; Hirofumi Kato; Shuetsu Fukushi; Masayuki Saijo
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

Review 5.  HSV-2: in pursuit of a vaccine.

Authors:  Christine Johnston; David M Koelle; Anna Wald
Journal:  J Clin Invest       Date:  2011-12-01       Impact factor: 14.808

6.  Sequence Analysis of Herpes Simplex Virus 1 Thymidine Kinase and DNA Polymerase Genes from over 300 Clinical Isolates from 1973 to 2014 Finds Novel Mutations That May Be Relevant for Development of Antiviral Resistance.

Authors:  Susanne Schmidt; Kathrin Bohn-Wippert; Peter Schlattmann; Roland Zell; Andreas Sauerbrei
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

7.  Longitudinal Characterization of Herpes Simplex Virus (HSV) Isolates Acquired From Different Sites in an Immune-Compromised Child: A New HSV Thymidine Kinase Mutation Associated With Resistance.

Authors:  Andrew H Karaba; Laura K Cohen; Taly Glaubach; Sarah J Kopp; Jennifer L Reichek; Hawke H Yoon; Xiaotian T Zheng; William J Muller
Journal:  J Pediatric Infect Dis Soc       Date:  2012-05-03       Impact factor: 3.164

8.  Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.

Authors:  Sonia Burrel; Zaïna Ait-Arkoub; Delphine Voujon; Claire Deback; Emiliana P Abrao; Henri Agut; David Boutolleau
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

9.  Genotypic Characterization of Herpes Simplex Virus Type 1 Isolates in Immunocompromised Patients in Rio de Janeiro, Brazil.

Authors:  Amanda Perse da Silva; Amanda de Oliveira Lopes; Yasmine Rangel Vieira; Adilson José de Almeida; Fernando Samuel Sion; Beatriz Grinsztejn; Sandra Wagner; Vanessa Salete de Paula
Journal:  PLoS One       Date:  2015-09-25       Impact factor: 3.240

10.  Net -1 frameshifting on a noncanonical sequence in a herpes simplex virus drug-resistant mutant is stimulated by nonstop mRNA.

Authors:  Dongli Pan; Donald M Coen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.